Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial

Froesch, P; Mark, M; Rothschild, SI; Li, QY; Godar, G; Rusterholz, C; Leibundgut, EO; Schmid, S; Colombo, I; Metaxas, Y; Konig, D; Sessa, C; Gautschi, O; Fruh, M

Froesch, P (corresponding author), Oncol Inst Southern Switzerland, Via Osped, CH-6500 Bellinzona, Switzerland.

LUNG CANCER, 2021; 156 (): 91

Abstract

Background: KRAS mutations are found in 20-25 % of non-squamous non-small cell lung cancer (NSCLC) and therapies targeting the RAS/MEK/ERK pathway are......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索